Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort).

Scailteux, Lucie-Marie; Campillo-Gimenez, Boris; Kerbrat, Sandrine; Despas, Fabien; Mathieu, Romain; Vincendeau, Sébastien; Balusson, Frédéric; Happe, André; Nowak, Emmanuel; Oger, Emmanuel

Scailteux, Lucie-Marie; Campillo-Gimenez, Boris; Kerbrat, Sandrine; Despas, Fabien; Mathieu, Romain; Vincendeau, Sébastien; Balusson, Frédéric; Happe, André; Nowak, Emmanuel; Oger, Emmanuel.

Am J Epidemiol ; 190(3): 413-422, 2021 02 01.

Article in En | MEDLINE | ID: mdl-32944756

Subject(s)

Androstenes/therapeutic use; Antineoplastic Agents/therapeutic use; Phenylthiohydantoin/analogs & derivatives; Prostatic Neoplasms, Castration-Resistant/drug therapy; Prostatic Neoplasms, Castration-Resistant/mortality; Aged; Aged, 80 and over; Benzamides; Comorbidity; Humans; Male; Nitriles; Phenylthiohydantoin/therapeutic use; Proportional Hazards Models; Prostate-Specific Antigen; Survival Analysis

Key words

SNDS; abiraterone; enzalutamide; metastatic castration-resistant prostate cancer; overall survival; population-based study

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylthiohydantoin / Prostatic Neoplasms, Castration-Resistant / Androstenes / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male Language: En Journal: Am J Epidemiol Year: 2021 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google